Recently, mouse-specific OX40 monoclonal antibodies (mAbs) were developed and applied for immune positron emission tomography (immunoPET) imaging in proof-of-principle studies to predict responses to cancer vaccines (38) or T cell response to glioblastoma (39) in preclinical mouse models. The gene discussed is TNFRSF4; the disease is cancer.